scholarly journals Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment

2020 ◽  
Vol 10 (12) ◽  
pp. 964
Author(s):  
Jogender Mehla ◽  
Pooja Gupta ◽  
Monika Pahuja ◽  
Deepti Diwan ◽  
Diksha Diksha
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Curcuma Longa ◽  
Neurofibrillary Tangle ◽  
Herbal Medicines ◽  
Memory Loss ◽  
Centella Asiatica ◽  
Evolvulus Alsinoides ◽  
Cholinesterase Inhibitory Activity

Cognitive impairment, associated with ageing, stress, hypertension and various neurodegenerative disorders including Parkinson’s disease and epilepsy, is a major health issue. The present review focuses on Alzheimer’s disease (AD), since it is the most important cause of cognitive impairment. It is characterized by progressive memory loss, language deficits, depression, agitation, mood disturbances and psychosis. Although the hallmarks of AD are cholinergic dysfunction, β-amyloid plaques and neurofibrillary tangle formation, it is also associated with derangement of other neurotransmitters, elevated levels of advanced glycation end products, oxidative damage, neuroinflammation, genetic and environmental factors. On one hand, this complex etiopathology makes a response to commonly used drugs such as donepezil, rivastigmine, galantamine and memantine less predictable and often unsatisfactory. On the other hand, it supports the use of herbal medicines due to their nonspecific antioxidant and anti-inflammatory activity and specific cholinesterase inhibitory activity. The popularity of herbal medicines is also increasing due to their perceived effectiveness, safety and affordability. In the present article, the experimental and clinical evidence have been reviewed for various Indian herbal medicines such as Centella asiatica, Bacopa monnieri, Curcuma longa, Clitoria ternatea, Withania somnifera, Celastrus paniculatus, Evolvulus alsinoides, Desmodium gangeticum, Eclipta alba, Moringa oleifera and Convolvulus pluricaulis, which have shown potential in cognitive impairment. Some commonly available herbal formulations for memory impairment in India have also been reviewed.

scholarly journals Herbal Approaches for Alzheimer Disease: A Review

2021 ◽  
pp. 311-324
Author(s):  
. Yoggeta ◽  
Deepika Bhatia ◽  
Manisha Bhatti
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Alzheimer Disease ◽  
Curcuma Longa ◽  
Herbal Medicines ◽  
Centella Asiatica ◽  
Current Treatment ◽  
Cognitive Disability ◽  
The Cost ◽  
Convolvulus Pluricaulis

"Plague of the Twenty-First Century," or “Alzheimer disease” is anneuro-degenerative disease that influenced the world's elderly population. The prevalence of Alzheimer's disease is expected to increase to one hundred thirty-five million by 2050, with no treatment(s) currently available to cure or monitor the disease's progression. The current treatment(s) have lesscapability to manage symptoms or delay disease development, and they can cause serious side effects. The cost of overall treatment is high for both the patients and their caregivers or family members. As an example, there is an serious requirement to find safer alternative treatments for better management of Alzheimer's disease. The various Indian herbal medicines such as Centella asiatica,Celastruspaniculatus Curcuma longa, Clitoriaternatea,Bacopa monnieri, Withania somnifera, has been reviewed in this article. Eclipta alba, Desmodiumgangeticum, Evolvulusalsinoides, Moringa oleifera, and Convolvulus pluricaulis are among the plants that have shown promising effect in the treatment related to cognitive disability.

scholarly journals Promoting Conversations About Cognitive Decline Between Older Adults and Primary Care Providers

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 157-158
Author(s):  
Benjamin Olivari ◽  
Christopher Taylor ◽  
Nia Reed ◽  
Lisa McGuire
Keyword(s):  
Alzheimer’S Disease ◽  
Primary Care ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Chronic Conditions ◽  
Memory Loss ◽  
Primary Care Providers ◽  
Subjective Cognitive Decline ◽  
Care Providers

Abstract Alzheimer’s disease and related dementias often begin with symptoms of mild memory loss, eventually leading to more severe cognitive impairment, functional impairment, and ultimately, death. Data from the Behavioral Risk Factor Surveillance System core questions related to chronic diseases and from the cognitive decline optional module on subjective cognitive decline (SCD) from the years 2015-2018 were aggregated across the participating 50 states, D.C., and Puerto Rico for this analysis. Among U.S. adults aged 65 years and older, only 39.8% (95%CI=37.6-42.1) of those experiencing SCD reported discussing their SCD symptoms with a healthcare provider. The prevalence of discussing SCD symptoms with a provider was higher among those with at least one chronic condition than among those with no chronic conditions. 30.7% (28.6-32.8) of those aged 65 years and older reported that their SCD led to functional limitations and 28.8% (26.5-31.2) needed assistance with day-to-day activities. For patients aged 65 years and older, Welcome to Medicare visits and Medicare Annual Wellness Visits are critically underutilized primary care access points. Primary care providers can manage chronic conditions, cognitive health, and initiate referrals for testing. Efforts to promote the use of toolkits and diagnostic codes that are available to primary care providers to initiate conversations about memory loss with patients may be utilized to improve detection, diagnosis, and planning for memory problems. Discussions may lead to earlier detection and diagnosis of cognitive impairment, such as Alzheimer’s disease, or other treatable conditions such as delirium or pressure in the brain and avoid costly hospitalizations.

Technological prospecting of music therapy in Alzheimer's disease

2021 ◽  
Vol 10 (16) ◽  
pp. e443101622316
Author(s):  
Murilo Bastos ◽  
Kelby Cavalheiro de Mendonça ◽  
Valquiria Camargo Lins ◽  
Eduardo Muzzolon ◽  
Deise Mara Soares ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Music Therapy ◽  
Memory Loss ◽  
Active Therapy ◽  
Pharmacological Interventions ◽  
Limited Efficacy ◽  
Drug Treatments ◽  
The Subject

Alzheimer's disease (AD) is characterized by cognitive impairment and progressive memory loss and drug treatments have limited efficacy. Thus, non-pharmacological interventions, such as music therapy, have shown to be promising as supporting pharmacological treatment and, therefore, may arouse commercial interest regarding the development of this type of product. Thus, this study aims to carry out a patentometric survey on patent registrations with music therapy in the treatment of AD. A systematic search was carried out from 2000 to 2020 on the Orbti-Questel website, searching for documents referring to music therapies in AD. The terms “Alzheimer music methodology active therapy” and “Alzheimer music methodology passive therapy” were used. After searching, reading, and excluding duplicate results, we found four patent families referring to music therapy in AD and all were selected as a result, which was considered little compared to the number of studies published on the subject.

scholarly journals Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer’s disease and mild cognitive impairment

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Massimiliano Castellazzi ◽  
Simone Patergnani ◽  
Mariapina Donadio ◽  
Carlotta Giorgi ◽  
Massimo Bonora ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Late Onset ◽  
Memory Loss ◽  
Serum Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Cellular Processes

AbstractDementia is a neurocognitive disorder characterized by a progressive memory loss and impairment in cognitive and functional abilities. Autophagy and mitophagy are two important cellular processes by which the damaged intracellular components are degraded by lysosomes. To investigate the contribution of autophagy and mitophagy in degenerative diseases, we investigated the serum levels of specific autophagic markers (ATG5 protein) and mitophagic markers (Parkin protein) in a population of older patients by enzyme-linked immunosorbent assay. Two hundred elderly (≥65 years) outpatients were included in the study: 40 (20 F and 20 M) with mild-moderate late onset Alzheimer’s disease (AD); 40 (20 F and 20 M) affected by vascular dementia (VAD); 40 with mild cognitive impairment (MCI); 40 (20 F and 20 M) with “mixed” dementia (MD); 40 subjects without signs of cognitive impairment were included as sex-matched controls. Our data indicated that, in serum samples, ATG5 and Parkin were both elevated in controls, and that VAD compared with AD, MCI and MD (all p < 0.01). Patients affected by AD, MD, and MCI showed significantly reduced circulating levels of both ATG5 and Parkin compared to healthy controls and VAD individuals, reflecting a significant down-regulation of autophagy and mitophagy pathways in these groups of patients. The measurement of serum levels of ATG5 and Parkin may represent an easily accessible diagnostic tool for the early monitoring of patients with cognitive decline.

Microlinguistic aspects of the oral narrative in patients with Alzheimer's disease

2010 ◽  
Vol 23 (3) ◽  
pp. 404-412 ◽  
Author(s):  
Juliana Onofre de Lira ◽  
Karin Zazo Ortiz ◽  
Aline Carvalho Campanha ◽  
Paulo Henrique Ferreira Bertolucci ◽  
Thaís Soares Cianciarullo Minett
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Memory Loss ◽  
Oral Narrative ◽  
Elderly Subjects ◽  
Word Finding ◽  
Picture Description ◽  
Lexical Errors

ABSTRACTBackground: Alzheimer's disease (AD) is characterized by memory loss and cognitive impairment. Phonological, syntactic, semantic and discursive aspects of language may also be affected. Analysis of micro- and macrolinguistic abilities of discourse may assist in diagnosing AD. The aim of this study was to identify changes in the discourse (lexical errors and syntactic index) of AD patients.Methods: 121 elderly subjects narrated a story based on a seven-figure picture description.Results: Patients with AD presented more word-finding difficulties, revisions and repetitions, and the syntactic index was lower than controls.Conclusion: Performance in microlinguistics at the lexical and syntactic levels was lower than expected in participants with AD.

scholarly journals Diagnosis of Alzheimer’s Disease with Ensemble Learning Classifier and 3D Convolutional Neural Network

Sensors ◽  
2021 ◽  
Vol 21 (22) ◽  
pp. 7634
Author(s):  
Peng Zhang ◽  
Shukuan Lin ◽  
Jianzhong Qiao ◽  
Yue Tu
Keyword(s):  
Neural Network ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Convolutional Neural Network ◽  
Ensemble Learning ◽  
Memory Loss ◽  
Main Tool ◽  
Disease Diagnosis

Alzheimer’s disease (AD), the most common type of dementia, is a progressive disease beginning with mild memory loss, possibly leading to loss of the ability to carry on a conversation and respond to environments. It can seriously affect a person’s ability to carry out daily activities. Therefore, early diagnosis of AD is conducive to better treatment and avoiding further deterioration of the disease. Magnetic resonance imaging (MRI) has become the main tool for humans to study brain tissues. It can clearly reflect the internal structure of a brain and plays an important role in the diagnosis of Alzheimer’s disease. MRI data is widely used for disease diagnosis. In this paper, based on MRI data, a method combining a 3D convolutional neural network and ensemble learning is proposed to improve the diagnosis accuracy. Then, a data denoising module is proposed to reduce boundary noise. The experimental results on ADNI dataset demonstrate that the model proposed in this paper improves the training speed of the neural network and achieves 95.2% accuracy in AD vs. NC (normal control) task and 77.8% accuracy in sMCI (stable mild cognitive impairment) vs. pMCI (progressive mild cognitive impairment) task in the diagnosis of Alzheimer’s disease.

scholarly journals The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer’s Disease

2020 ◽  
Vol 21 (13) ◽  
pp. 4674 ◽  
Author(s):  
Xavier O. Scott ◽  
Marisa E. Stephens ◽  
Marie C. Desir ◽  
W. Dalton Dietrich ◽  
Robert W. Keane ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Memory Loss ◽  
Adaptor Protein ◽  
Therapeutic Window ◽  
Likelihood Ratios ◽  
Predictive Values ◽  
Protein Levels

Mild cognitive impairment (MCI) is characterized by memory loss in the absence of dementia and is considered the translational stage between normal aging and early Alzheimer’s disease (AD). Patients with MCI have a greater risk of advancing to AD. Thus, identifying early markers of MCI has the potential to increase the therapeutic window to treat and manage the disease. Protein levels of the inflammasome signaling proteins apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and interleukin (IL)-18 were analyzed in the serum of patients with MCI, AD and healthy age-matched donors as possible biomarkers, as well as levels of soluble amyloid precursor proteins α/β (sAPP α/β) and neurofilament light (NfL). Cut-off points and positive and negative predictive values, as well as receiver operator characteristic (ROC) curves, likelihood ratios and accuracy were determined for these proteins. Although the levels of ASC were higher in MCI and AD than in age-matched controls, protein levels of ASC were higher in MCI than in AD cases. For control vs. MCI, the area under the curve (AUC) for ASC was 0.974, with a cut-off point of 264.9 pg/mL. These data were comparable to the AUC for sAPP α and β of 0.9687 and 0.9068, respectively, as well as 0.7734 for NfL. Moreover, similar results were obtained for control vs. AD and MCI vs. AD. These results indicate that ASC is a promising biomarker of MCI and AD.

scholarly journals Potential of Caffeine in Alzheimer’s Disease—A Review of Experimental Studies

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 537
Author(s):  
Piotr Londzin ◽  
Milena Zamora ◽  
Beata Kąkol ◽  
Aleksandra Taborek ◽  
Joanna Folwarczna
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Treatment Options ◽  
Experimental Studies ◽  
Memory Loss ◽  
Epidemiological Data ◽  
Caffeine Intake ◽  
Protective Mechanisms ◽  
Beneficial Effects

Alzheimer’s disease (AD) is the most common type of dementia leading to progressive memory loss and cognitive impairment. Considering that pharmacological treatment options for AD are few and not satisfactory, increasing attention is being paid to dietary components that may affect the development of the disease. Such a dietary component may be caffeine contained in coffee, tea or energy drinks. Although epidemiological data suggest that caffeine intake may counteract the development of cognitive impairment, results of those studies are not conclusive. The aim of the present study is to review the existing experimental studies on the efficacy of caffeine against AD and AD-related cognitive impairment, focusing on the proposed protective mechanisms of action. In conclusion, the reports of studies on experimental AD models generally supported the notion that caffeine may exert some beneficial effects in AD. However, further studies are necessary to elucidate the role of caffeine in the effects of its sources on cognition and possibly AD risk.

Sign in / Sign up

Export Citation Format

Share Document